Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment
NCT ID: NCT07118813
Last Updated: 2025-08-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
400 participants
OBSERVATIONAL
2025-08-31
2026-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Based on CT Radiomics for Distinguishing Benign From Malignant Renal Tumors and Assessing Their Aggressiveness.
NCT07060248
Optimising Renal Tumour Management Through Artificial Intelligence Modules
NCT06714916
Development of AI Model for Renal Tumor Diagnosis Using CT and Lab Tests
NCT06761742
Predicting Immunotherapy Response and Survival of Lung Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Lung)
NCT07059923
Predicting HIF-2α Levels in Clear Cell Kidney Cancer Using Machine Learning
NCT07332923
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Aged \> 18 years old;
3. At least one abdominal CT scan before treatment;
4. Tissue biopsy pathological examination confirmed the diagnosis of renal cell carcinoma.
Exclusion Criteria
2. Incomplete clinical data or loss of follow-up;
3. Presence of another primary malignancy other than renal cell carcinoma;
4. Unclear pathological diagnosis.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Union Hospital，Tongji Medical College，Huazhong University of Science and Technology
Wuhan, Hubei, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-0672
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.